Our findings suggest that ENV-mediated induction of nitrosative stress via activation of TLR4 results in an overall reduction of the oligodendroglial differentiation capacity, thereby contributing to remyelination failure. Therefore, pharmacological or antibody-mediated inhibition of ENV may prevent the blockade of myelin repair in the diseased or injured central nervous system.

Beyond immune cell modulation, this monoclonal antibody may therefore help to overcome the oligodendroglial differentiation blockade in MS.

Dear Sirs, Originated in Wuhan, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading globally and the number of patients with coronavirus disease 2019 (COVID-19) keeps increasing. The clinical features of COVID-19 include high fever and respiratory syndromes; however, neurological symptoms have also been reported recently [1]. We describe the first case of COVID-19 that initially exhibited non-epileptic seizures (convulsive syncope) in autonomic dysfunction.On April 2, 2020, a 70-year-old woman was admitted to our hospital due to recurrent non-epileptic seizures/convulsive syncopes. On the day of admission, the patient was found unconscious in her bathroom after a fall. Apart from an enuresis, other stigmata for epileptic seizures, such as delayed reorientation or tongue biting, were not reported. Creatine kinase was elevated in serum, presumably due to the fall. In the last days before admission, the patient had syncopated three times and one of the three syncopes cooccurred with convulsions.The patient had suffered from syncopes-mainly triggered by sudden pain-over the last years, but not recently. She regularly received methotrexate and etanercept due to psoriatic arthritis. Additional preexistent conditions included neuropathic pain, treated with pregabalin, and paroxysmal atrial fibrillation.Upon admission, angina pectoris and vertigo were denied. Also fever, cough, a sore throat and loss of gustation or